Growth hormone treatment impact on growth rate and final height of patients who received HSCT with TBI or/and cranial irradiation in childhood: a report from the French Leukaemia Long-Term Follow-Up Study (LEA).

Date publication

mai 2012

Auteurs

Membres identifiés du Cancéropôle Est :
Pr CHASTAGNER Pascal

Tous les auteurs :
Isfan F, Kanold J, Merlin E, Contet A, Sirvent N, Rochette E, Poiree M, Terral D, Carla-Malpuech H, Reynaud R, Pereira B, Chastagner P, Simeoni MC, Auquier P, Michel G, Demeocq F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/21725370

Résumé

The literature contains a substantial amount of information about factors that adversely influence the linear growth in up to 85% of patients undergoing haematopoietic SCT (HSCT) with TBI and/or cranial irradiation (CI) for acute leukaemia (AL). By contrast, only a few studies have evaluated the impact of growth hormone (GH) therapy on growth rate and final height (FH) in these children. We evaluated growth rates during the pre- and post-transplant periods to FH in a group of 25 children treated with HSCT (n=22), TBI (n=21) or/and CI (n=8) for AL and receiving GH therapy. At the start of GH treatment, the median height Z-score was -2.19 (-3.95 to 0.02), significantly lower than at AL diagnosis (P

Référence

Bone Marrow Transplant. 2012 May;47(5):684-93